Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Akanksha Bakshi

Eton Pharmaceuticals Names James Gruber Finance Chief

  • Eton Pharmaceuticals Inc (NASDAQ:ETON) has appointed James Gruber as Chief Financial Officer effective immediately. He succeeds Wilson Troutman, who is retiring.
  • Mr. Troutman will remain with the company through May to ensure a smooth transition.
  • Mr. Gruber, most recently, was the U.S. Controller at Horizon Therapeutics (NASDAQ:HZNP) for seven years, where he oversaw accounting activities for the company during its rapid growth. Before Horizon, Mr. Gruber spent 14 years at Abbott Laboratories, where he held various financial and accounting leadership positions.
  • Earlier today, Eton Pharmaceuticals received final approval from the U.S. Food and Drug Administration (FDA) for its cysteine hydrochloride abbreviated new drug application (ANDA), a bioequivalent generic of Exela Pharma Sciences' Elcys™.
  • Eton was granted 180 days of generic exclusivity as a result of being the first ANDA submitted against the reference product.
  • Eton is currently engaged with Exela in paragraph IV litigation regarding the validity of Exela's cysteine patents. The trial was held in March 2022, and a decision is expected in the third quarter of 2022.
  • Price Action: ETON shares are trading lower by 3.41% at $3.68 during the post-market session on Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.